BUSINESS

Lilly Discloses Japan Filing for Orforglipron, Starting with Obesity

By Shinya Sato February 6, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Quick Look: Lilly has filed its oral GLP-1 agent orforglipron in Japan, beginning with obesity. Approval could come in 2026, with a separate diabetes filing also planned this year. Eli Lilly has now confirmed that it has filed for…

To read the full story

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026
January 6, 2026

BUSINESS

Lilly Discloses Japan Filing for Orforglipron, Starting with Obesity
February 6, 2026
Ono Recalls Certain Opdivo Lots over Possible Metal Contamination
February 6, 2026
Eisai Snares Japan Commercial Rights to Henlius’ PD-1 Inhibitor
February 6, 2026
Takeda Rolls Out 31-Foot Containers for Drug Transport
February 6, 2026
Okajima to Take Helm of Asahi Kasei Pharma in April
February 6, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key

By Sakura Kono

Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…